Preparation method of epoxide intermediates for triazole antifungal drugs

By constructing two consecutive chiral centers for triazole antifungal drug epoxy intermediates in one step through alkenylation and asymmetric epoxidation reactions, the problems of low synthesis efficiency and low purity in existing technologies are solved, realizing efficient and simple preparation of epoxy intermediates, which are suitable for large-scale production.

CN118063446BActive Publication Date: 2026-11-17SICHUAN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410010774.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-04
Publication Date
2026-11-17
Estimated Expiration
2044-01-04

AI Technical Summary

Technical Problem

Existing methods for synthesizing key epoxy intermediates of triazole antifungal drugs are inefficient, involve cumbersome steps, and produce products with low optical purity, making it difficult to efficiently and easily construct two continuous chiral centers.

Method used

Using 2-difluorophenyl-2-acetoxylate compounds as starting materials, Z-trisubstituted olefin compounds are constructed in one step through alkenylation and asymmetric epoxidation reactions. With specific catalysts and conditions, chiral epoxides are directly generated, including the use of tris(dimethylamino)phosphine, Grignard addition, Smithsonian or Jacobsen asymmetric epoxidation reactions, etc.

Benefits of technology

This method enables the efficient and convenient construction of two consecutive chiral centers in the epoxy intermediate of triazole antifungal drugs. The product has high optical purity, the reaction conditions are mild, it is suitable for large-scale production, and the cost is low and the operation is simple.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118063446B_ABST
    Figure CN118063446B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of chemical drug synthesis, specifically relating to a novel method for synthesizing a key epoxy intermediate for triazole antifungal drugs. This epoxy compound is a common intermediate in the synthesis of antifungal drugs and derivatives such as efinaconazole, isavuconazole, revuconazole, and abaconazole, and has significant value in drug synthesis and antifungal drug development. This invention uses α-ketoester compound 1 as a starting material, and prepares (Z)-olefins with high stereoselectivity via tris(dimethylamino)phosphine-promoted alkenylation. After reduction to form (Z)-allyl alcohol, the key epoxy intermediate is then prepared through highly enantioselective asymmetric epoxidation and other transformations; and further applied to the synthesis of triazole antifungal drugs. This method features a simple route, high synthetic efficiency, and high optical purity of the product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a method for preparing epoxide intermediates of triazole antifungal drugs. Background Technology

[0002] Fungal infections are common diseases that endanger human health, especially invasive fungal infections, which have extremely high morbidity and mortality rates in immunocompromised populations. The increasing risk of infection and the growing number of susceptible individuals have significantly increased the demand for the discovery and synthesis of antifungal drugs. However, the eukaryotic nature of fungi presents a significant challenge in developing anti-infective drugs with a broad antibacterial spectrum and minimal side effects in humans. Since the FDA approval of the triazole antifungal drug fluconazole in 1989, strategies based on the desymmetry of fluconazole's structure have become an important approach to discovering novel antifungal drugs, leading to the development of several chiral triazole antifungal drugs and candidates with good antifungal activity and safety, such as voriconazole, isaconazole, abaconazole, and rivconazole. Figure 1 This breakthrough in the treatment of fungal infections represents a significant advancement. Among the limited range of anti-infective drugs currently used clinically, triazole antifungals play an indispensable role, widely used to treat various superficial fungal infections and even high-risk invasive fungal infections. The strategy for modifying the structure of fluconazole primarily involves replacing one of its triazole rings with a different heterocycle and introducing a methyl group on the α-carbon of its tertiary alcohol structure. This structural change creates two adjacent chiral centers at C2 and C3. Structure-activity relationship analysis shows that the C2 chiral center and its substituents are key structures of the pharmacophore in triazole drugs, while the methyl group and heterocyclic substituents at the C3 chiral center are highly effective structural modifications for improving the structure of the first-generation antifungal drug fluconazole, playing a crucial role in altering its antibacterial spectrum, pharmacokinetics, antibacterial activity, and side effects.

[0003] Given that the aforementioned triazole antifungal drugs contain two consecutive chiral centers in their structures, and that the tetrasubstituted quaternary carbon chiral center contains a tertiary hydroxyl substituent, the chiral epoxy intermediate (2R,3S)-6 is currently widely used. Figure 1The key epoxy intermediate 6 is a crucial intermediate for obtaining triazole drugs and candidates such as ivermectin (2), rafconazole (3), and isaconazole (4). Through the ring-opening reaction of epoxy intermediate 6 with a nucleophilic reagent, triazole antifungal drugs and drug candidates with different structures can be rapidly prepared. Therefore, this epoxy intermediate has become a highly valuable intermediate in the fields of pharmaceutical synthesis and new drug development. Consequently, the field of drug synthesis has made great efforts towards the asymmetric synthesis of the key epoxy intermediate 6. However, although theoretically, the asymmetric catalytic synthesis of chiral intermediate 6 is an ideal way to achieve efficient, highly selective, and green synthesis of triazole antifungal drugs, the stereoselective construction of 2R,3S chiral centers is quite difficult. Currently, most asymmetric synthetic methods rely on using D- or L-lactic acid as the chiral pool (Org. Process Res. Dev. 2009, 13, 716-728). Only a few methods for the asymmetric catalytic synthesis of chiral epoxides have been reported, and these methods have limitations in terms of conversion steps, synthetic efficiency, and product optical purity. A brief overview of these methods for the asymmetric catalytic synthesis of epoxide 6 is as follows:

[0004] 1) such as Figure 2 As shown in Figure A, in 1995, Bennett et al. (Synlett 1995, 11, 1110) used difluoroacetophenone derivative 7 as a substrate to synthesize E-type trisubstituted olefin 8 via the Wittig reaction. Then, through several cumbersome and low-yield conversions, 8 was converted into the desired Z-type olefin 9. After deacetylation of 9, the resulting product was converted into the crucial epoxy intermediate 6 (76% ee) via Sharpless epoxidation. This method pioneered the asymmetric catalytic synthesis of epoxy intermediate 6, but the difficulty in obtaining Z-type olefin 9 and the low enantioselectivity of the epoxidation reaction limited its further application.

[0005] 2) such as Figure 2 As shown in B, Shibasaki et al. (J.Org.Chem.2014,79,3272-3278) also used compound 7 as a starting material to construct a tetrasubstituted quaternary carbon chiral center via catalytic asymmetric silylation of a ketone. However, the enantioselectivity of product 11 was still not good enough (80% ee). In the process of converting 11 into the key intermediate 6, it is necessary to go through steps such as reducing the cyano group to an aldehyde, introducing a triazole ring, and adding the aldehyde to a methyl Grignard reagent to synthesize intermediate 12 to establish a trisubstituted chiral center. This process is not only cumbersome, but also produces diastereomers (with poor diastereoselectivity, dr=6:1). The main product needs to be recrystallized to improve optical purity.

[0006] 3) such as Figure 2As shown in C, Zhang et al. (J. Am. Chem. Soc. 2017, 139, 10733-10741.) converted alkenyl compound 13 into chiral intermediate 14 via a palladium-catalyzed asymmetric allylic substitution reaction, constructing a tetrasubstituted quaternary carbon chiral center with high enantioselectivity (94% ee). However, intermediate 14 requires multiple steps, including vinyl epoxidation (dr = 7:1), ring opening, and epoxide formation, to be converted into the target compound 6, reducing the overall synthetic efficiency. Furthermore, the use of expensive palladium catalysts in the key asymmetric catalytic reaction results in high costs, which is detrimental to the large-scale synthesis of triazole antifungal drugs.

[0007] 4) such as Figure 2 As shown in D, in 2020, Feng et al. (Org. Lett. 2021, 23, 6961-6966) used an asymmetric catalytic epoxidation system composed of a chiral dioxane ligand / scandium trifluoromethanesulfonate / hydrogen peroxide to convert a disubstituted olefin 17 into a chiral epoxide compound 18 (88% ee) with moderate enantioselectivity. Compound 18 undergoes nucleophilic epoxide ring-opening with triazole to convert to 19, producing a diastereomer (dr = 7:1). The major isomer is then converted to the target epoxide intermediate 6 through several steps of reduction of the ketone carbonyl group to a hydroxyl group / re-formation of an epoxide. This route also suffers from insufficient enantioselectivity of asymmetric catalysis and low overall synthetic efficiency.

[0008] This shows that the current methods for the efficient synthesis of the key epoxy intermediate 6 are still very limited. It is essential to develop a new method for its synthesis, which will not only benefit the industrial synthesis of triazole antifungal drugs / candidates, but also the research and development of triazole antifungal drugs / candidates. Summary of the Invention

[0009] The purpose of this invention is to overcome the shortcomings of existing technologies, such as low synthesis efficiency, cumbersome steps, and low optical purity of products, and to provide a new method for the efficient preparation of key intermediates of triazole antifungal drugs. The method of this invention features readily available raw materials, high enantioselectivity of asymmetric catalytic reactions, short steps, high synthesis efficiency, strong practicality, and high optical purity of the products.

[0010] The objective of this invention is achieved through the following technical solution: a method for synthesizing epoxide intermediates of triazole antifungal drugs, comprising the following steps:

[0011] S1. Using 2-difluorophenyl-2-acetoxylate compound 1 as a starting material, Z-trisubstituted olefin compound 2 is prepared by method A or method B;

[0012]

[0013] In the formula, R is methyl or ethyl; difluorophenyl is 2,4-difluorophenyl or 2,5-difluorophenyl;

[0014] Method A: 2-Difluorophenyl-2-acetoxylate compound 1 is alkenylated with an ethylating agent under the action of tris(dimethylamino)phosphine to generate (Z)-trisubstituted olefin compound 2 with high selectivity;

[0015]

[0016] Method B: 2-Difluorophenyl-2-acetoxylate compound 1 is reacted with an ethyl Grignard reagent by Grignard addition reaction to prepare tertiary alcohol intermediate 3, which is then subjected to elimination reaction to generate (Z)-trisubstituted olefin compound 2 with high selectivity.

[0017]

[0018] S2 and (Z)-trisubstituted olefin compound 2 were reacted by reducing the ester group to a primary hydroxyl group to give (Z)-allyl alcohol compound 4;

[0019]

[0020] S3 and allyl alcohol compound (Z)-4 undergo a catalytic asymmetric epoxidation reaction to yield chiral epoxide compound 5; the asymmetric epoxidation reaction is one of the following: the Stern asymmetric epoxidation reaction, the asymmetric epoxidation reaction catalyzed by a metal catalyst-chiral dihydroxyoxime ligand, and the Jacobsen asymmetric epoxidation reaction.

[0021]

[0022] S4. The primary hydroxyl group of chiral epoxy compound 5 undergoes a substitution reaction with 1,2,4-triazole to obtain the epoxy intermediate 6; that is, after the chiral epoxy compound 5 reacts with methanesulfonyl chloride, the resulting sulfonated intermediate undergoes a substitution reaction with 1,2,4-triazole to obtain the key epoxy intermediate 6; this step has been disclosed in the literature of Bennett et al., as pointed out in the background art.

[0023]

[0024] Furthermore, in step S1, the ethylating agent in method A is bromoethane, iodoethane, or ethyl trifluoromethanesulfonate.

[0025] And / or, the solvent for the alkenylation reaction is toluene, dichloromethane, dichloroethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, methanol, or water;

[0026] And / or, the olefination reaction is carried out at a temperature of –40°C to 0°C;

[0027] And / or, the temperature of the post-treatment of the olefination reaction is 20℃~80℃.

[0028] Furthermore, in method B of step S1, the ethyl Grignard reagent is ethyl magnesium chloride, ethyl magnesium bromide, or ethyl magnesium iodide.

[0029] And / or, the solvent for the Grignard addition reaction is tetrahydrofuran, diethyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, or acetonitrile;

[0030] And / or, the additive used in the Grignard addition reaction is one or more of zinc chloride, lithium chloride, (trimethylsilyl)methylmagnesium chloride, cuprous chloride, cuprous iodide, cuprous cyanide and cuprous bromide;

[0031] And / or, the Grignard addition reaction is carried out at a temperature of –78°C to 25°C;

[0032] And / or, the reagents used in the elimination reaction are thionyl chloride and pyridine.

[0033] Furthermore, in step S2, the reducing agent in the reaction where the reduced ester group is a primary hydroxyl group is lithium aluminum hydride, lithium borohydride, sodium borohydride, potassium borohydride, triethyl lithium borohydride, or diisobutylaluminum hydride.

[0034] And / or, the additive in the reaction where the reduced ester group is a primary hydroxyl group is a Lewis acid, preferably aluminum trichloride, copper sulfate, zinc chloride, cerium chloride, or lithium chloride;

[0035] And / or, the solvent for the reaction in which the reduced ester group is a primary hydroxyl group is methanol, ethanol, isopropanol, tetrahydrofuran, dichloromethane or toluene;

[0036] And / or, the reaction temperature for the reaction in which the reduced ester group is a primary hydroxyl group is –78°C to 25°C.

[0037] Furthermore, in step S3, the oxidant used in the Schereschewsky asymmetric epoxidation reaction is potassium persulfate complex salt.

[0038] And / or, the base used in the said Smith asymmetric epoxidation reaction is potassium carbonate;

[0039] And / or, the additive used in the Smith asymmetric epoxidation reaction is tetra-n-butylammonium hydrogen sulfate;

[0040] And / or, one of the solvents used in the said Schereschewsky asymmetric epoxidation reaction is sodium tetraborate buffer or disodium ethylenediaminetetraacetate buffer, and the other is one or two of acetonitrile, dimethyl formaldehyde, dipropylene glycol dimethyl ether, dimethoxymethane, ethylene glycol dimethyl ether and dioxane;

[0041] And / or, the catalyst used in the said Smith asymmetric epoxidation reaction is

[0042]

[0043] Furthermore, in step S3, the metal catalyst used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxyoxime ligand is vanadium bis(acetylacetone)oxyVO(acac)2 or vanadium triisopropoxide VO(O)2. i Pr)3, acetylacetone molybdenum oxide MoO2(acac)2, tert-butoxide zirconium Zr(O) t Bu)4 or tert-butanol hafnium(O) t Bu)4;

[0044] And / or, the dihydroxyxamic acid ligand used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxyxamic acid ligand is...

[0045] Preferred

[0046] And / or, the oxidant used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxamic acid ligand is peroxytert-butanol (TBHP), cumene hydroperoxide (CHP), or triphenylmethyl hydroperoxide (THP).

[0047] And / or, the reaction solvent used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxyoxime ligand is dichloromethane, dichloroethane, chloroform or toluene;

[0048] And / or, the reaction temperature catalyzed by the metal catalyst-chiral dihydroxyoxime ligand is –20°C to 25°C.

[0049] Furthermore, in step S3, the catalyst used in the Jacobsen asymmetric epoxidation reaction is...

[0050] All are catalysts commonly used in the Jacobsen asymmetric epoxidation reaction method; preferably...

[0051] And / or, the oxidant used in the Jacobsen asymmetric epoxidation reaction is sodium hypochlorite (NaClO), m-chloroperoxybenzoic acid (m-CPBA), peroxytert-butanol (TBHP), hydrogen peroxide (H2O2), isopropylphenyl hydroperoxide (CHP), triphenylmethyl hydroperoxide (THP), iodobenzoylbenzene (PhIO), PhINNs, iodophenyl diacetic acid (PhI(OAc)2), or potassium persulfate complex salt (Oxone);

[0052] And / or, the additives used in the Jacobsen asymmetric epoxidation reaction are 2,6-dimethylpyridine, 1,8-diazabicyclo(DBU), 1,2,4-triazole, N-methylmorpholine (NMM), tetramethylguanidine (TMG), pyridine, 4-dimethylaminopyridine (DMAP), N-methylpiperazine, dimethylpyrazine, phenylimidazole, or 2-phenylimidazole;

[0053] And / or, the reaction solvent used in the Jacobsen asymmetric epoxidation reaction is dichloromethane, dichloroethane, chloroform, toluene, tetrahydrofuran, N,N-dimethylformamide, acetone, ethanol or hexafluoroisopropanol;

[0054] And / or, the reaction temperature of the Jacobsen asymmetric epoxidation reaction is –78°C to –40°C.

[0055] The present invention also provides a method for synthesizing the above-mentioned triazole antifungal drug epoxy intermediate for use in the synthesis of chiral triazole antifungal drugs and chiral triazole derivatives.

[0056] Furthermore, the chiral triazole antifungal drugs include rivconazole, ivorconazole, isaconazole, abaconazole, and YC071 (structural formula see [link]). Figure 1 ).

[0057] The beneficial effects of this invention are:

[0058] 1. The method for synthesizing triazole antifungal drug epoxy intermediates provided by this invention can construct two consecutive chiral centers of triazole antifungal drug epoxy intermediates in one step. Compared with Bennett's method for constructing two consecutive chiral centers of epoxy in one step, it can not only easily obtain Z-type olefins, but also offers more options for asymmetric epoxidation methods and higher enantioselectivity. It truly provides a feasible method for constructing two chiral centers in one step for the industrial synthesis of triazole antifungal drug epoxy intermediates. Compared with other stepwise methods for constructing two centers of epoxy, this invention is not only simpler in steps, but also has advantages such as higher enantioselectivity, no need for recrystallization to improve optical purity of the product, no generation of diastereomers, and higher synthesis efficiency.

[0059] 2. The method for synthesizing triazole antifungal drug epoxy intermediates provided by the present invention, by limiting specific conditions, yields target products with the highest optical purity to date compared to methods reported in the literature.

[0060] 3. The method for synthesizing triazole antifungal drug epoxy intermediates provided by the present invention can prepare (Z)-olefins with high stereoselectivity through the alkenylation reaction of tris(dimethylamino)phosphine-promoted α-keto ester compound (1). Compared with the method reported by Bennett, which first prepares (E)-olefins through the Wittig reaction and then isomerizes them into (Z)-olefins, it has the characteristics of high efficiency and practicality, and overcomes the problem that it is difficult to obtain Z-olefins in the method of constructing two chiral centers of epoxy in one step.

[0061] 4. The method for synthesizing triazole antifungal drug epoxy intermediates provided by the present invention employs different catalytic asymmetric epoxidation methods. Among them, the asymmetric epoxidation catalyzed by metal complex-chiral hydroxamic acid ligand and the Jacobsen epoxidation method can both prepare precursor compound 5 of key epoxy intermediate 6 with excellent enantioselectivity, which is a significant improvement compared with the Sharpless asymmetric epoxidation (76% ee) reported by Bennett.

[0062] 5. The method for synthesizing triazole antifungal drug epoxy intermediates provided by this invention has mild reaction conditions. In particular, the key alkenylation reaction and asymmetric epoxidation reaction can be carried out on a scale of tens of grams, which lays a good foundation for the large-scale synthesis of triazole drugs and the discovery of novel triazole drugs.

[0063] 6. The method for synthesizing triazole antifungal drug epoxy intermediates provided by this invention uses readily available and simple raw materials. The reagents used in subsequent transformations are all common chemical reagents and do not require special preparation. In particular, the reagents used in the key olefination and asymmetric epoxidation reactions are inexpensive, resulting in a low-cost synthesis method. Furthermore, the operation and post-processing of each reaction step are simple, the synthesis efficiency is high, and the method is highly operable. Attached Figure Description

[0064] Figure 1 This is a chiral triazole antifungal drug discovered in the prior art based on a fluconazole structure desymmetry strategy;

[0065] Figure 2 Several methods for the catalytic asymmetric synthesis of the key chiral epoxy intermediate 6 in existing technologies;

[0066] Figure 3 A flowchart of the synthesis method of triazole antifungal drug epoxy intermediate provided by the present invention;

[0067] Figure 4 This is the HPLC chromatogram of the racemic mixture of compound 5 in Example 4; the running information is as follows:

[0068] Column: DAIICEL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 92:8; Flow rate: 1.0 mL / min; 25℃. Peak information (wavelength: 254 nm): t isomer-1 = 8.627 minutes, t isomer-2 = 9.901 minutes.

[0069]

[0070] Figure 5 The HPLC chromatogram of the enantiomer of compound 5 in Example 4 is shown below; the running information is as follows:

[0071] Column: DAICL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 92:8; Flow rate: 1.0 mL / min; 25 °C. Peak information (wavelength: 254 nm): t major = 8.574 minutes, t minor = 9.874 minutes.

[0072]

[0073]

[0074] Figure 6 The HPLC chromatogram of the racemic mixture of compound 5 in Example 7 is shown below; the running information is as follows:

[0075] Column: DAIICEL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 92:8; Flow rate: 1.0 mL / min; 25℃. Peak information (wavelength: 254 nm): t isomer-1 = 8.609 min, t isomer-2 = 9.903 min.

[0076]

[0077] Figure 7 The HPLC chromatogram of compound (+)-5 in Example 7 is shown below; the running information is as follows:

[0078] Column: DAICL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 92:8; Flow rate: 1.0 mL / min; 25 °C. Peak information (wavelength: 254 nm): t minor = 8.594min, t major = 9.809 min.

[0079]

[0080] Figure 8 The HPLC chromatogram of the racemic mixture of compound 5 in Example 16 is shown below; the running information is as follows:

[0081] Column: DAICL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 95:5; Flow rate: 0.6 mL / min; 25℃. Peak information (wavelength: 254 nm): t isomer-1 =19.516min,t isomer-2 =22.965min.

[0082]

[0083] Figure 9 The HPLC chromatogram of compound (+)-5 in Example 16 is shown below; the running information is as follows:

[0084] Column: DAICL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 95:5; Flow rate: 0.6 mL / min; 25℃. Peak information (wavelength: 254 nm): t minor =19.291min,t major =22.588min.

[0085]

[0086] Figure 10 This is the HPLC chromatogram of the racemic 6-component epoxy intermediate from Example 26; the running information is as follows:

[0087] Column: DAICEL CHIRALCEL OD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 90:10, Flow rate: 1.0 mL / min, 25℃. Peak information (wavelength: 262 nm): t isomer-1 =22.976min,t isomer-2 =29.013min.

[0088]

[0089] Figure 11 This is the HPLC chromatogram of optically pure compound 6 from Example 26; the running information is as follows:

[0090] Column: DAICEL CHIRALCEL OD-H, 4.6 × 250 mm, 5 μm; Solvent: Hexane: i-PrOH = 90:10, Flow rate: 1.0 mL / min, 25℃. Peak information (wavelength: 262 nm): t major =22.921min,t minor =29.384min.

[0091]

[0092] Figure 12 Example 26 Epoxy Intermediate 6 1 H-NMR spectrum;

[0093] Figure 13 Example 26 Epoxy Intermediate 6 13 C-NMR spectrum;

[0094] Figure 14 Example 26 Epoxy Intermediate 6 19 F-NMR spectrum. Detailed Implementation

[0095] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings, but the scope of protection of the present invention is not limited to the following description.

[0096] Example 1 Method A Preparation of (Z)-Trisubstituted Olefin Compound 2

[0097]

[0098] Anhydrous zinc chloride (764 mg, 5.60 mmol, 1.2 eq.) and anhydrous lithium chloride (594 mg, 14.0 mmol, 3.0 eq.) were weighed into a dry round-bottom flask. Argon gas was introduced, and anhydrous tetrahydrofuran (5.0 mL) and trimethylsilylmethylmagnesium chloride (1.3 M in THF, 2.15 mL, 2.80 mmol, 0.6 eq.) were added. After stirring at room temperature for 1 hour, ethyl magnesium bromide (1 M in THF, 14.0 mL, 14.0 mmol, 3.0 eq.) was added, and the reaction was allowed to proceed at room temperature for 1 hour. The reaction was then cooled to 0 °C, and a tetrahydrofuran solution (8.0 mL) of α-keto ester compound 1 (1.00 g, 4.67 mmol, 1.0 eq.) was slowly added dropwise to the reaction flask using a syringe pump over 2 hours. The reaction was allowed to proceed overnight at this temperature. After the reaction was monitored to be complete by TLC, it was quenched with saturated ammonium chloride aqueous solution, extracted with ethyl acetate (30 mL × 3), and the combined organic phases were washed with saturated brine (30 mL × 1) and dried over anhydrous magnesium sulfate. The crude product was filtered and concentrated, then purified by silica gel column chromatography (petroleum ether: ethyl acetate = 50:1) to give a pale yellow oil 3 (980 mg, 86%). TLC: (petroleum ether: ethyl acetate = 10:1, v / v), R f =0.5. 1 H NMR (400MHz, CDCl3): δ7.58–7.50(m,1H),6.91–6.83(m,1H),6.82–6.75(m,1H),4.32–4. 16(m,2H),3.84(s,1H),2.25–2.17(m,2H),1.24(t,J=7.2Hz,3H),0.94(t,J=7.2Hz,3H). 19 F NMR (376MHz, CDCl3): δ-108.21–-108.33(m),-110.64–-110.81(m). 13 C NMR (100MHz, CDCl3): δ174.6,162.8(dd,J=212.8,12.2Hz), 161.4(dd,J=214.8,12.2Hz), 128.8(dd,J=9.6,5.4Hz), 125.3(dd,J=12.2 ,4.0Hz),110.9(dd,J=20.7,3.6Hz),104.4(dd,J=26.8,25.2Hz),76.0(d,J=1.8Hz),62.5,30.0(d,J=2.5Hz),13.98,7.65.IR(neat):ν max =3497,2980,2941,1729,1615,1500,1235,1136,1099,971,849cm-1 .HRMS(ESI)m / z:[M+H] + calcd.for C 12 H 15 F2O3 + ,245.0984; found,245.0979.

[0099] Compound 3 (900 mg, 3.69 mmol, 1.0 eq.) was weighed into a dry round-bottom flask, purged with argon, and dissolved in anhydrous dichloromethane (27.0 mL). Anhydrous pyridine (630 μL, 7.38 mmol, 2.0 eq.) was added at room temperature. The reaction was brought to 0 °C, and a pyridine solution (18.0 mL) of thionyl chloride (1.33 mL, 18.45 mmol, 5.0 eq.) was slowly added. The reaction was allowed to proceed overnight at this temperature. After the reaction was confirmed to be complete by TLC, the mixture was quenched with water, extracted with dichloromethane (50 mL × 3), washed with 1 N hydrochloric acid (50 mL × 1), washed with saturated sodium bicarbonate solution (50 mL × 1), washed with water (50 mL × 1), and washed with saturated saline solution (50 mL × 1). The crude product, after drying and filtration to concentrate anhydrous magnesium sulfate, was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 500:1–200:1) to give a pale yellow oil (Z)-2 (648 mg, 78%). TLC: (petroleum ether:ethyl acetate = 10:1, v / v), R f =0.5. 1 HNMR (400MHz, CDCl3): δ7.23–7.16(m,1H),6.88–6.73(m,2H),6.32(q,J=7.6 Hz, 1H), 4.23 (q, J = 6.8Hz, 2H), 2.16 (d, J = 7.2Hz, 3H), 1.26 (t, J = 6.8Hz, 3H). 19 F NMR (376MHz, CDCl3): δ-109.9–-110.1(m),-110.9–-111.1(m). 13 C NMR (100MHz, CDCl3): δ166.5,162.5(dd,J=247.2,11.8Hz), 159.9(dd,J=248.3,11.9Hz), 141.2,131.1(dd,J=9.5,5.0 Hz),129.0,123.5(dd,J=15.0,4.0Hz),111.1(dd,J=20.9,3.6Hz),103.7(t,J=25.6Hz),60.7,16.0,14.1.IR(neat):ν max=3082,2983,2939,1717,1501,1194,1139,1096,848cm -1 .HRMS(ESI)m / z:[M+H] + calcd.for C 12 H 13 F2O2 + ,227.0878;found,227.0883.

[0100] Example 2 Method B Preparation of (Z)-trisubstituted olefin compound 2

[0101]

[0102] The reaction flask was purged with argon gas, and under argon protection, dry acetonitrile (190 mL) was added. The mixture was then cooled to -40 °C. While stirring, EtI (9.00 mL, 112 mmol, 1.2 eq.) and P(NMe2)3 (20.4 mL, 112 mmol, 1.2 eq.) were added sequentially. The resulting mixture was stirred at -40 °C for 20 minutes, then heated to 25 °C and stirred for 2 hours. The reaction was then further heated to 60 °C and continued for 2 hours. TLC monitoring confirmed complete reaction. The reaction mixture was quenched with water (100 mL), and the aqueous layer was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with saturated brine (100 mL × 1), dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 500:1–200:1) to give a pale yellow oil (Z)-2 (15.6 g, 74%, Z:E > 20:1). TLC: (petroleum ether:ethyl acetate = 10:1, v / v). f =0.5. 1 H NMR (400MHz, CDCl3): δ7.23–7.16(m,1H),6.88–6.73(m,2H),6.32(q,J=7.6Hz,1H),4.23(q,J=6.8Hz,2H),2.16(d,J=7.2Hz,3H),1.26(t,J=6.8Hz,3H). 19 F NMR (376MHz, CDCl3): δ-109.9–-110.1(m),-110.9–-111.1(m). 13C NMR (100MHz, CDCl3): δ166.5,162.5(dd,J=247.2,11.8Hz), 159.9(dd,J=248.3,11.9Hz), 141.2,131.1(dd,J=9.5,5.0 Hz),129.0,123.5(dd,J=15.0,4.0Hz),111.1(dd,J=20.9,3.6Hz),103.7(t,J=25.6Hz),60.7,16.0,14.1.IR(neat):ν max =3082,2983,2939,1717,1501,1194,1139,1096,848cm -1 HRMS (ESI) + )m / z:[M+H] + calcd.for C 12 H 13 F2O2 + ,227.0878;found,227.0883.

[0103] Example 3: Preparation of (Z)-Allyl alcohol compound 4

[0104]

[0105] The reaction flask was purged with argon gas. Under argon protection, a dry tetrahydrofuran solution (200 mL) of compound (Z)-2 (15.0 g, 66.4 mmol, 1.0 eq.) was added, and the mixture was cooled to -20 °C. DIBAL-H (110 mL, 166 mmol, 2.5 eq.) was added dropwise with stirring. The resulting mixture was reacted at -20 °C for 2 hours, then quenched with a saturated sodium potassium tartrate aqueous solution (150 mL). The aqueous layer was extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with saturated brine (200 mL × 1), dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8:1) to give a pale yellow oil (Z)-4 (11.5 g, 94%). TLC: (petroleum ether: ethyl acetate = 3:1, v / v). f =0.5.

[0106] 1 H NMR (400MHz, CDCl3): δ7.28–7.21(m,1H),6.87–6.76(m,2H),5.81(q,J=7.2Hz,1H),4.50(s,2H),1.88(d,J=7.2Hz,3H),1.46(s,1H). 19F NMR (376MHz, CDCl3): δ-111.8–-111.1(m),-112.0–-112.2(m). 13 C NMR (100MHz, CDCl3): δ162.2(dd,J=217.7,14.3Hz), 159.7(dd,J=215.3,14.3Hz), 135.2(d,J=1.9Hz), 131.2(dd,J=9.3,6.0Hz), 130.0,125.7(dd,J=14.8,3.9Hz),111.2(dd,J=20.8,3.6Hz),103.9(dd,J=26.8,25.0Hz),60.23(d,J=3.3Hz),13.9.IR(neat):ν max =3346,2921,1499,1137,1094,954,846cm -1 HRMS (ESI) + )m / z:[M+H] + calcd.for C 10 H 11 F2O + ,185.0772; found,185.0774.

[0107] Example 4: Synthesis of chiral epoxides using the Shih-style asymmetric epoxidation reaction method 5

[0108]

[0109] Compound (Z)-4 (184 mg, 1.0 mmol, 1.0 eq.) was dissolved in a CH3CN-DMM mixed solvent (15 mL, 1:2, v / v). While stirring, sodium borate / disodium ethylenediaminetetraacetate buffer (10 mL, 0.05 M solution of Na2B4O7·10H2O in 4 × 10⁻⁶ mL solution) was added sequentially. -4 M aqueous Na2(EDTA)), n-Bu4NHSO4 (15 mg, 0.040 mmol), and Steinstein catalyst C1 (77.5 mg, 0.30 mmol, 0.3 eq.) were added. The resulting mixture was cooled to 0 °C, and potassium persulfate complex salt Oxone (850 mg, 1.38 mmol, 1.38 eq.) and disodium ethylenediaminetetraacetate solution (4 × 10⁻⁶) were slowly added to it through a dropping funnel. -4A mixture of M (6.5 mL) was added dropwise over 1 hour. Simultaneously with the above dropwise addition, an aqueous solution of potassium carbonate (800 mg, 5.80 mmol) (6.5 mL) was slowly added. After the reaction was complete as monitored by TLC, the reaction solution was diluted with water and extracted with dichloromethane (15 mL × 3). The organic layers were combined, washed with saturated sodium chloride aqueous solution (15 mL × 1), dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 12:1) to give a pale yellow oil 5 (158 mg, 79%). HPLC analysis (DAICEL CHIRALCEL AD-H, 4.6 × 250 mm, 5 μm, n-hexane:i-PrOH = 92:8, flow rate: 1 mL / min, 25℃, λ = 254 nm): t major =8.574min,t minor = 9.874 min.

[0110] Under the above reaction conditions, replacing the C1 catalyst with its enantiomer yields epoxide 5, with an enantiomer ee value of 89%.

[0111] Examples 5-6: Synthesis of chiral epoxides using the Shih-style asymmetric epoxidation reaction method.

[0112]

[0113] The synthesis steps of Examples 5-6 are the same as those of Example 4. The oxidant, additives, solvents and reaction temperatures used in the reaction are as shown in the synthesis route, and the amounts are the same as in Example 4. The only difference between the examples is that different Smith catalysts were used in the synthesis process.

[0114]

[0115]

[0116] Example 7: Synthesis of chiral epoxides via asymmetric epoxidation catalyzed by a metal catalyst and chiral dihydroxyoxime ligand.

[0117]

[0118] Dissolve 10 mol% of dihydroxamic acid ligand L2 in toluene (1.0 mL), and add VO (O2) to the solution while stirring. iPr)3 (10 mol%) was added, and the resulting mixture was stirred at room temperature for 1 hour and then cooled to 0°C. Then, a toluene solution (1.0 mL) of peroxytert-butanol (147 μL, 5.5 M in decane, 1.5 eq.) and compound (Z)-5 (100 mg, 0.540 mmol, 1.0 eq.) was added sequentially. After the reaction was monitored by TLC until complete, water (2 mL) was added to quench the reaction, and the aqueous layer was extracted with ethyl acetate (2 mL × 3). The organic layers were combined, washed with saturated sodium chloride aqueous solution (2 mL × 1), dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 12:1) to give a pale yellow oil 5 (86.4 mg, 80%). HPLC analysis (DAICEL CHIRALCEL AD-H, 4.6×250mm, 5μm, n-hexane: i-PrOH=92:8, flow rate: 1mL / min, 25℃, λ=254nm): t minor =8.594min,t major =9.809min.ee=95%.

[0119] Examples 8-11: Synthesis of chiral epoxides via asymmetric epoxidation catalyzed by a metal catalyst and chiral dihydroxyoxime ligand.

[0120]

[0121] The synthesis steps were the same as in Example 7. The oxidant, additives, solvents, and reaction temperatures used in the reaction were all as shown in the synthesis route, and the amounts were the same as in Example 7. The only difference between the examples was that different dihydroxyoxime ligands were used in the synthesis process.

[0122]

[0123] Examples 12-13: Synthesis of chiral epoxides via asymmetric epoxidation catalyzed by a metal catalyst and chiral dihydroxyoxime ligand.

[0124]

[0125] The synthesis steps are the same as in Example 7. The ligands, oxidants, additives, and solvents used in the reaction are all as shown in the synthesis route, and the amounts are the same as in Example 7. The only difference between the examples is that the reaction temperature of the synthesis process is different.

[0126] Group reaction temperature Yield ee Example 12 -20℃ 73% 93% Example 13 25℃ 64% 88%

[0127] Examples 14-15: Synthesis of chiral epoxides via asymmetric epoxidation catalyzed by a metal catalyst and chiral dihydroxyoxime ligand.

[0128]

[0129] The synthesis steps are the same as in Example 7. The ligands, oxidants, additives, and solvents used in the reaction are all as shown in the synthesis route, and the amounts are the same as in Example 7. The only difference between the examples is the amount of metal catalyst and ligand.

[0130] Group <![CDATA[VO(O i Pr)3(x mol%)]]> L2(y mol%) Yield ee Example 14 1 2 66% 91% Example 15 2.5 5 77% 92%

[0131] Example 16: Synthesis of chiral epoxides 5 via Jacobsen asymmetric epoxidation reaction

[0132]

[0133] Enol (Z)-4 (1.00 g, 5.43 mmol, 1.0 eq.), (R,R)-Mn Salen catalyst (345 mg, 0.543 mmol, 0.1 eq.) and imidazole (1.85 g, 27.2 mmol, 5.0 eq.) were weighed into a dry round-bottom flask and dissolved in acetone (30 mL). The mixture was cooled to -78 °C, and m-chloroperoxybenzoic acid (2.75 g, 13.6 mmol, 5.0 eq.) was added. The mixture was reacted at this temperature for 3 h. After the reaction was completed by TLC monitoring, the mixture was filtered through diatomaceous earth, and the acetone was removed from the filtrate under reduced pressure. The reaction was quenched with 2N sodium hydroxide solution (50 mL), extracted with ethyl acetate (20 mL × 3), and the combined organic phases were washed with water (20 mL × 1), washed with saturated brine (20 mL × 1), and dried over anhydrous magnesium sulfate. The crude product, after filtration and concentration, was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 12:1) to give a light brown oily substance 7 (695 mg, 64%, 99.1% ee). TLC: (petroleum ether: ethyl acetate = 3:1, v / v), R f =0.4.[α] 25 =24.3 (0.63 g / 100 mL, CDCl3). 1 H NMR (400MHz, CDCl3): δ7.41–7.34(m,1H),6.90–6.75(m,2H),4.15–4.07(m,1H),3.9 1–3.85(m,1H),3.10(q,J=5.6Hz,1H),1.93(t,J=6.0Hz,1H),1.49(d,J=5.6Hz,3H). 19 F NMR (376MHz, CDCl3): δ-110.3–-110.4(m),-112.8–-112.9(m). 13C NMR (100MHz, CDCl3): δ163.7(dd,J=235.1,11.6Hz), 160.2(dd,J=234.6,12.1Hz), 129.8(dd,J=9.6,6.0Hz), 122.7(dd,J=1 5.1, 3.7Hz), 111.3 (dd, J = 21.2, 3.6Hz), 103.7 (t, J = 25.3Hz), 63.1 (d, J = 2.8Hz), 61.3 (d, J = 1.3Hz), 60.6, 13.6.IR (neat): ν max =3414,2964,2930,1618,1600,1505,1098,964,847cm -1 .HRMS(ESI)m / z:[M+H] + calcd.for C 10 H 11 F2O2 + ,201.0722;found,201.0724。

[0134] Examples 17-25: Synthesis of chiral epoxides via Jacobsen asymmetric epoxidation reaction.

[0135]

[0136] The synthesis steps are the same as in Example 16. The ligands, oxidants, additives, solvents, and reaction temperatures used in the reaction are as shown in the reaction formulas and tables. The reagent equivalents and catalysts are the same as in Example 16. The differences between the examples are: the reaction temperature, reaction solvent, and the type of oxidant or additive in the synthesis process.

[0137] Group Oxidizing agent additive solvent reaction temperature Yield ee Example 17 m-CPBA NMO <![CDATA[CH2Cl2]]> -78℃ 66% 85% Example 18 m-CPBA NMO <![CDATA[CHCl3]]> -60℃ 46% 87% Example 19 m-CPBA NMO <![CDATA[CH3CN]]> -40℃ 42% 85% Example 20 m-CPBA NMO acetone -78℃ 45% 86% Example 21 m-CPBA imidazole <![CDATA[CH2Cl2]]> -78℃ 55% 92% Example 22 m-CPBA imidazole MeOH -78℃ 55% 99% Example 23 m-CPBA imidazole <![CDATA[CHCl3]]> -60℃ 61% 97% Example 24 m-CPBA pyrimidine <![CDATA[CH2Cl2]]> -78℃ 59% 99% Example 25 <![CDATA[H2O2]]> imidazole acetone -78℃ 55% 92%

[0138] Example 26 Preparation of epoxy intermediate 6

[0139]

[0140] Substrate 8 (1.00 g, 4.95 mmol, 1.0 eq.) was weighed into a round-bottom flask, dissolved in dichloromethane (20 mL), and heated to 0 °C. Triethylamine (1.37 mL, 9.90 mmol, 2.0 eq.) and methanesulfonyl chloride (0.570 mL, 7.42 mmol, 1.5 eq.) were added sequentially, and the mixture was reacted at this temperature for 30 min. After the reaction was complete as monitored by TLC, water was added to quench the reaction, followed by extraction with dichloromethane (20 mL × 3), washing with saturated saline solution (20 mL × 1), drying over anhydrous magnesium sulfate, and concentrating under reduced pressure. The crude product was dissolved in N,N-dimethylformamide (20 mL), followed by the addition of triazole (664 mg, 9.90 mmol, 2.0 eq.) and potassium carbonate (1.37 g, 9.90 mmol, 2.0 eq.). The mixture was reacted at room temperature for 2 h, then at 50 °C overnight. After the reaction was monitored by TLC, the mixture was quenched with water, extracted with ethyl acetate (50 mL × 3), and the combined organic phases were washed with water (50 mL × 1), washed with saturated saline solution (50 mL × 1), and dried over anhydrous magnesium sulfate. The crude product was filtered and concentrated, then purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1) to give a white solid 9 (1.13 g, 90%). TLC: (petroleum ether: ethyl acetate = 1:1, v / v), R f =0.5.HPLC analysis(DAICELCHIRALCEL OD-H,4.6×250mm,5μm,n-hexane:i-PrOH=90:10,flow rate:1mL / min,25℃,λ=262nm):t major =22.921min,t minor =29.384min,ee>99%.TLC:(petroleum ether:EtOAc=1:1,v / v),R f =0.5.[α] D 25 =-7.2(c 0.67,CHCl3).Melting point:80-83℃. 1 H NMR (400MHz, CDCl3): δ7.95(s,1H),7.80(s,1H),7.04-6.95(m,1H),6.80-6.66(m,2H),4. 87(d,J=14.4Hz,1H), 4.42(d,J=14.6Hz,1H), 3.18(q,J=5.6Hz,1H), 1.63(d,J=5.6Hz,3H). 19 FNMR (376MHz, CDCl3): δ-108.64–-108.84(m),-112.67–-112.86(m). 13C NMR (100MHz, CDCl3): δ162.9 (dd, J=249.1, 11.9Hz), 161.1 (dd, J=246.9, 12.0Hz), 151.9, 143.6, 129.4 (dd, J=9.7, 5.5Hz), 1 20.8(dd,J=14.5,3.6Hz),111.6(dd,J=21.2,3.5Hz),103.8(t,J=25.2Hz),60.4,59.7,51.60(d,J=2.8Hz),13.9.IR(neat):ν max =3115,3001,2930,1617,1600,1506,1268,1136,1098,1024cm -1 HRMS (ESI) + )m / z:[M+H] + calcd.for C 12 H 12 F2N3O + ,252.0943; found,252.0941.

[0141] The above description is merely a preferred embodiment of the present invention. It should be understood that the present invention is not limited to the forms disclosed herein and should not be construed as excluding other embodiments. It can be used in various other combinations, modifications, and environments, and can be altered within the scope of the concept described herein through the above teachings or related technologies or knowledge. Modifications and variations made by those skilled in the art that do not depart from the spirit and scope of the present invention should be within the protection scope of the appended claims.

Claims

1. A process for the synthesis of an azole antifungal drug epoxide intermediate, characterized in that, Includes the following steps: S1, prepared from 2-difluorophenyl-2-oxoacetic acid compound 1 by method A or method B Z - a tri-substituted alkene compound 2; In the formula, R is methyl or ethyl; difluorophenyl is 2,4-difluorophenyl or 2,5-difluorophenyl; Method A: 2-Difluorophenyl-2-acetoxylate compound 1 is alkenylated with an ethylating agent under the action of tris(dimethylamino)phosphine to generate (Z)-trisubstituted olefin compound 2 with high selectivity; ; The EtX ethylating agent is bromoethane, iodoethane, or ethyl trifluoromethanesulfonate. Method B: 2-Difluorophenyl-2-acetoxylate compound 1 is reacted with an ethyl Grignard reagent by Grignard addition reaction to prepare tertiary alcohol intermediate 3, which is then subjected to elimination reaction to generate (Z)-trisubstituted olefin compound 2 with high selectivity. ; The EtMgX ethyl Grignard reagent is ethyl magnesium chloride, ethyl magnesium bromide, or ethyl magnesium iodide. S2, (R2)2 Z - the tri-substituted olefin compound 2 is reacted by reducing the ester group to a primary hydroxyl group to obtain Z - the allyl alcohol compound 4; S3, allyl alcohol compounds ( Z Chiral epoxide 5 is obtained by catalytic asymmetric epoxidation of 4-4; the asymmetric epoxidation reaction is one of the following: the Stern asymmetric epoxidation reaction, the asymmetric epoxidation reaction catalyzed by a metal catalyst-chiral dihydroxyoxime ligand, and the Jacobsen asymmetric epoxidation reaction. ; The metal catalyst used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxyoxime ligand is vanadium bis(acetylacetone)oxy, vanadium triisopropoxide, molybdenum acetylacetone, zirconium tert-butoxide, or hafnium tert-butoxide. The asymmetric epoxidation reaction catalyzed by the metal catalyst and chiral dihydroxyoxime ligand uses the following dihydroxyoxime ligand: , , , or ; The oxidant used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxyoxime ligand is tert-butanol peroxide (TBHP), cumene hydroperoxide (CHP), or triphenylmethyl hydrogen peroxide (THP). The reaction solvent used in the asymmetric epoxidation reaction catalyzed by the metal catalyst-chiral dihydroxyoxime ligand is dichloromethane, dichloroethane, chloroform, or toluene; The reaction temperature catalyzed by the metal catalyst and chiral dihydroxyoxime ligand is -20 °C to 25 °C. S4, chiral epoxy compound 5 reacts with methanesulfonyl chloride, and the resulting sulfonated intermediate undergoes a substitution reaction with 1,2,4-triazole to obtain the epoxy intermediate 6. 。 2. The method for synthesizing the triazole antifungal drug epoxy intermediate according to claim 1, characterized in that, In step S1 of method A, the solvent for the alkenylation reaction is toluene, dichloromethane, dichloroethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, methanol, or water; And / or, the alkenylation reaction is carried out at a temperature of –40 °C to 0 °C; And / or, the temperature of the post-treatment of the alkenylation reaction is 20℃ ~ 80℃.

3. The method for synthesizing the triazole antifungal drug epoxy intermediate according to claim 1, characterized in that, In step S1, the solvent for the Grignard addition reaction is tetrahydrofuran, diethyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, or acetonitrile. And / or, the additive used in the Grignard addition reaction is one or more of zinc chloride, lithium chloride, (trimethylsilyl)methylmagnesium chloride, cuprous chloride, cuprous iodide, cuprous cyanide and cuprous bromide; And / or, the Grignard addition reaction is carried out at a temperature of –78 °C to 25 °C; And / or, the reagents used in the elimination reaction are thionyl chloride and pyridine.

4. The method for synthesizing the triazole antifungal drug epoxy intermediate according to claim 1, characterized in that, In step S2, the reducing agent in the reaction where the reduced ester group is a primary hydroxyl group is lithium aluminum hydride, lithium borohydride, sodium borohydride, potassium borohydride, triethyl lithium borohydride, or diisobutylaluminum hydride. And / or, the reduced ester group is a primary hydroxyl group, and the additive in the reaction is a Lewis acid; And / or, the solvent for the reaction in which the reduced ester group is a primary hydroxyl group is methanol, ethanol, isopropanol, tetrahydrofuran, dichloromethane or toluene; And / or, the reaction temperature for the reaction in which the reduced ester group is a primary hydroxyl group is –78 °C to 25 °C.

5. The method for synthesizing the triazole antifungal drug epoxy intermediate according to claim 1, characterized in that, In step S3, the oxidant used in the Smith asymmetric epoxidation reaction is potassium persulfate complex salt; And / or, the base used in the said Smith asymmetric epoxidation reaction is potassium carbonate; And / or, the additive used in the Smith asymmetric epoxidation reaction is tetra-n-butylammonium hydrogen sulfate; And / or, one of the solvents used in the said Shi asymmetric epoxidation reaction is sodium tetraborate buffer or disodium ethylenediaminetetraacetate buffer, and the other is one or two of acetonitrile, dimethyl formaldehyde, dipropylene glycol dimethyl ether, dimethoxymethane, ethylene glycol dimethyl ether and dioxane; And / or, the catalyst used in the said Smith asymmetric epoxidation reaction is , or .

6. The method for synthesizing the triazole antifungal drug epoxy intermediate according to claim 1, characterized in that, In step S3, the catalyst used in the Jacobsen asymmetric epoxidation reaction is , , , , , or ; And / or, the oxidant used in the Jacobsen asymmetric epoxidation reaction is sodium hypochlorite (NaClO) or m-chloroperoxybenzoic acid (NaClO). m -CPBA), peroxytert-butanol (TBHP), hydrogen peroxide (H2O2), isopropylphenyl hydrogen peroxide (CHP), triphenylmethyl hydrogen peroxide (THP), iodobenzoylbenzene (PhIO), PhINNs, iodophenyl diacetic acid (PhI(OAc)2) or potassium persulfate complex salt (Oxone). And / or, the additives used in the Jacobsen asymmetric epoxidation reaction are 2,6-dimethylpyridine, 1,8-diazabicyclo(DBU), 1,2,4-triazole, N-methylmorpholine (NMM), tetramethylguanidine (TMG), pyridine, 4-dimethylaminopyridine (DMAP), N-methylpiperazine, dimethylpyrazine, benzopyrazole, or 2-phenylimidazolium; And / or, the reaction solvent used in the Jacobsen asymmetric epoxidation reaction is dichloromethane, dichloroethane, chloroform, toluene, tetrahydrofuran, N,N-dimethylformamide, acetone, ethanol or hexafluoroisopropanol; And / or, the reaction temperature of the Jacobsen asymmetric epoxidation reaction is –78℃ ~ –40℃.

7. The method for synthesizing the triazole antifungal drug epoxy intermediate according to any one of claims 1-6 is used for the synthesis of chiral triazole antifungal drugs and chiral triazole derivatives, characterized in that, The chiral triazole antifungal drugs include rivconazole, ivorconazole, isaconazole, abaconazole, and YC071, wherein the structural formula of YC071 is [insert structural formula here]. .

Citation Information

Patent Citations

  • 2,4-Dihalobiphenyl group-containing novel azole compound, and synthetic method and use thereof

    CN104788439A

  • Preparation method of triazole antifungal drug and intermediate thereof

    CN115872926A